Disclosure Of Effect Of Changes In Foreign Exchange Rates [Text Block]

Biotest AG - Filing #6464577

Concept	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	As at 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31
Disclosure of effect of changes in foreign exchange rates [text block]	D 7	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of information when currency is not exchangeable into another currency [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of information when foreign operation’s functional currency is not exchangeable into presentation currency [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of summarised financial information about foreign operation [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of summarised financial information about foreign operation [abstract]
Disclosure of summarised financial information about foreign operation [line items]
Non-current assets	—	—	—	6,245,000,000 EUR	—	—	—	—	—	6,544,000,000 EUR	—	—	—	—
Current assets	—	—	—	8,095,000,000 EUR	—	—	—	—	—	7,565,000,000 EUR	—	—	—	—
Non-current liabilities	—	—	—	7,432,000,000 EUR	—	—	—	—	—	5,267,000,000 EUR	—	—	—	—
Current liabilities	—	—	—	1,601,000,000 EUR	—	—	—	—	—	3,853,000,000 EUR	—	—	—	—
Revenue	7,262,000,000 EUR	—	—	—	—	—	—	—	6,846,000,000 EUR	—	—	—	—	—
Profit (loss)	264,000,000 EUR	– EUR	– EUR	—	– EUR	– EUR	264,000,000 EUR	– EUR	1,270,000,000 EUR	—	– EUR	– EUR	1,270,000,000 EUR	– EUR
Other comprehensive income	72,000,000 EUR	– EUR	– EUR	—	42,000,000 EUR	30,000,000 EUR	– EUR	– EUR	8,000,000 EUR	—	20,000,000 EUR	– EUR	– EUR	28,000,000 EUR
Comprehensive income	336,000,000 EUR	– EUR	– EUR	—	42,000,000 EUR	30,000,000 EUR	264,000,000 EUR	– EUR	1,278,000,000 EUR	—	20,000,000 EUR	– EUR	1,267,000,000 EUR	31,000,000 EUR